These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33395331)

  • 1. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
    Singh A
    Ann Intern Med; 2021 Jan; 174(1):JC3. PubMed ID: 33395331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.
    Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canouï E; Zerbit J; Carlier N; Terrier B; Kernéis S; Batista R; Treluyer JM; Zheng Y; Benaboud S
    Ther Drug Monit; 2021 Feb; 43(1):131-135. PubMed ID: 33230045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 10. Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
    Mazzotta V; Mazzaferri F; Lanini S; Mirandola M; Cozzi Lepri A; Vergori A; Savoldi A; Santoro A; Maccarrone G; Mastrorosa I; Simonetti O; Zottis F; Nicastri E; Rosini G; Rovigo L; Tavernaro L; Sarmati L; Tascini C; Girardi E; Cattelan AM; Antinori A; Tacconelli E;
    J Infect; 2024 Nov; 89(5):106294. PubMed ID: 39343244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
    Lu JM; Zhou AF; Zhang XB; Xu H; Wang XF; Ye QF; Shang FN; He YL; Ma SL; Cui YX; Chen RJ; Li XY; Zhai XW; Xu H; Li ZP
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):549-555. PubMed ID: 33506948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
    Owa AB; Owa OT
    J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.
    Tan DHS; Chan AK; Jüni P; Tomlinson G; Daneman N; Walmsley S; Muller M; Fowler R; Murthy S; Press N; Cooper C; Lee T; Mazzulli T; McGeer A
    Trials; 2021 Mar; 22(1):224. PubMed ID: 33752741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
    Zhang H; Wu W; Zheng Y; Fu Q; Chen P; Li J; Wu Z; Gu J; Li J; Liu L; Wu C; Long S; Xu B; Ling L; Fu Y; Wang C
    Ren Fail; 2024 Dec; 46(2):2385724. PubMed ID: 39282735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
    Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
    Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.